Is Elevance Health (ELV) Cheap As Argus Upgrades And 2026 Guidance Rises?

Simply Wall St · 11h ago

Argus just upgraded Elevance Health (ELV), and the company lifted its full-year 2026 adjusted earnings outlook to at least US$29.00 per share, putting fresh attention on its operating performance and profit trajectory.

At a share price of US$394.48, Elevance Health has slipped in the short term, with the 7-day share price return down 8.19% and the 30-day share price return down 9.13%. However, the year-to-date share price return of 11.36% and 1-year total shareholder return of 25.05% suggest the longer trend still leans constructive, despite a weaker three-year total shareholder return of negative 13.36%.

Scan for other health insurers and service providers that could be setting up for similar earnings and sentiment shifts using our curated list of solid balance sheet and fundamentals (24 results)

That upgrade and guidance bump have widened the gap between Elevance Health’s US$394.48 share price and a much higher band of value estimates. Is the market discount now justified by the numbers, or is it out of line with them?

Most Popular Narrative: 16.9% Undervalued

On the analyst consensus Narrative on Simply Wall St, Elevance Health screens as undervalued, with a fair value estimate of $474.57 against the recent $394.48 close. This frames the current discount through modeled earnings, margins, and a 7.28% discount rate.

Ongoing deployment of Elevance Health’s AI, analytics and digital platforms such as HealthOS and Sydney Health, including automated prior authorization and earlier visibility into medical cost trends, is expected to tighten medical cost management and support more stable net margins and earnings over time.

See why 120 investors see Elevance Health as 17% undervalued.

Result: Fair Value of $474.57 (UNDERVALUED)

Still, the Elevance Health story can change quickly if Medicaid margins remain under pressure or if higher medical costs outpace what pricing and care programs can absorb.

Find out about the key risks to this Elevance Health narrative.

Next Steps

If this Elevance Health story feels finely balanced between promise and pressure, do not wait for a consensus to harden. Instead, review the full picture of both risks and potential upsides and weigh them against your own expectations using 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has your attention, you can use that momentum and line up your next watchlist candidates before the market prices them more efficiently.